arrow_back Trending Legislation
Share share

Extended Medicare Support for Biosimilar Drugs

This bill aims to extend special payment increases for biosimilar biological products under the Medicare program until 2032. This means Medicare beneficiaries may continue to have access to these medications for a longer period, potentially impacting their treatment costs and access to modern therapies.
Key points
Extends payment increases for biosimilar products in Medicare from 2027 to 2032.
Potential impact on drug accessibility and costs for Medicare beneficiaries.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
Print number: HR 6400
Sponsor: Rep. Cárdenas, Tony [D-CA-29]
Process start date: 2023-11-14